1. 27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination. Issue 3 (September 2015) Authors: Arkenau, H.T.; Voskoboynik, M.; Infante, J.; Brenner, A.; Patel, M.; Borazanci, E.; Falchook, G.; Molife, L.R.; Pant, S.; Dean, E.; Pelosof, L.; Jones, S.; Rubino, C.; McCulloch, W.; Zhukova-Harrill, V.; Kemble, G.; O'Farrell, M.; Burris, H. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. (September 2015) Authors: Voss, M.; Gordon, M.S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D.; Kwak, E.L.; Cervantes, A.; Puzanov, I.; Pili, R.; Wang, D.; Jalal, S.; Pant, S.; Patel, M.; Neuwirth, R.; Zohren, F.; Infante, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EP-1381: Role of Metabolic Tumor Volume and Total Lesion Glycolysis on FDG-PET/CT in NSCLC treated with SBRT. (April 2018) Authors: Cabrera, J.; Infante, J.; Cruz, C.; Moreno, M.; Gonzalez, M.; Rayo, J.; Simon, P.; Ortiz, B.; Muñoz, J. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S754 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. (September 2019) Authors: Adarmes, A.D.; Almeria, M.; Alonso Losada, G.; Alonso Cánovas, A.; Alonso-Frech, F.; Arribas, S.; Ascunde Vidondo, A.; Aquilar, M.; Ávila, M.A.; Bernardo Lambrich, N.; Bejr-Kasem, H.; Blázquez Estrada, M.; Botí, M.; Cabello González, C.; Cabo López, I.; Caballol, N.; Cámara Lorenzo, A.; Carrillo,... Journal: Parkinsonism & related disorders Issue: Volume 66(2019) Page Start: 151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein. (December 2016) Authors: Shapiro, G.; Bedard, P.; Infante, J.; Bauer, T.; Prawira, A.; Laksin, O.; Weetall, M.; Baird, J.; Branstrom, A.; O'Mara, E.; Spiegel, R. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC). (December 2016) Authors: Meric-Bernstam, F.; Tannir, N.; Harding, J.; Voss, M.; Mier, J.; DeMichele, A.; Munster, P.; Patel, M.; Iliopoulos, O.; Owonikoko, T.; Whiting, S.; Orford, K.; Bennett, M.; Carvajal, R.; McKay, R.; Fan, A.; Telli, M.; Infante, J. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Reduced serum progranulin level might be associated with Parkinson's disease risk. Issue 12 (9th February 2013) Authors: Mateo, I.; González‐Aramburu, I.; Pozueta, A.; Vázquez‐Higuera, J. L.; Rodríguez‐Rodríguez, E.; Sánchez‐Juan, P.; Calero, M.; Dobato, J. L.; Infante, J.; Berciano, J.; Combarros, O. Journal: European journal of neurology Issue: Volume 20:Issue 12(2013:Dec.) Page Start: 1571 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. (June 2017) Authors: Kaplan, J.; Gordon, L.; Infante, J.; Popat, R.; Rambaldi, A.; Madan, S.; Patel, M.R.; Gritti, G.; El‐Sharkawi, D.; Chau, I.; Radford, J.; Perez De Oteyza, J.; Zinzani, P.; Iyer, S.; Faucette, S.; Sheldon‐Waniga, E.; Stumpo, K.; Shou, Y.; Carpio, C.; Bosch, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗